Gene and Protein Information
Species	TM	AA	Chromosomal Location	Gene Symbol	Gene Name	Reference
Human	1	435	12p13.31	LTBR	lymphotoxin beta receptor
Mouse	1	415	6 59.32 cM	Ltbr	lymphotoxin B receptor
Rat	-	-		Ltbr	lymphotoxin beta receptor

Previous and Unofficial Names

CD18 | LTbetaR | LT-beta receptor | LTBR | lymphotoxin beta receptor (TNFR superfamily, member 3) | TNFCR | TNFR2-RP | TNF receptor-related protein | TNFR III

Database Links
Alphafold	P36941 (Hs), P50284 (Mm)
ChEMBL Target	CHEMBL1250360 (Hs)
Ensembl Gene	ENSG00000111321 (Hs), ENSMUSG00000030339 (Mm), ENSRNOG00000019264 (Rn)
Entrez Gene	4055 (Hs), 17000 (Mm), 297604 (Rn)
Human Protein Atlas	ENSG00000111321 (Hs)
KEGG Gene	hsa:4055 (Hs), mmu:17000 (Mm), rno:297604 (Rn)
OMIM	600979 (Hs)
Pharos	P36941 (Hs)
UniProtKB	P36941 (Hs), P50284 (Mm)
Wikipedia	LTBR (Hs)

Natural/Endogenous Ligands
LIGHT {Sp: Human}
lymphotoxin β2α1 heterotrimer {Sp: Human}

Adaptor proteins (Human)

TRAF3, TRAF4, TRAF5

Other Binding Ligands
Key to terms and symbols		Click column headers to sort
Ligand Sp. Action Value Parameter Reference LIGHT {Sp: Human} Hs - - - ⤷ lymphotoxin β2α1 heterotrimer {Sp: Human} Hs - - - ⤷

Immunopharmacology Comments

Interaction of the lymphotoxin β receptor (LTBR) with its ligand is required for the development and organization of the secondary lymphoid organs and is involved in chemokine release (reported to induce interleukin 8 gene expression [2]). The LTBR pathway also drives expression of homeostatic chemokines (CCL19, CCL21, CXCL13) that are associated with the pathological development of ectopic lymphoid-like follicles in the exocrine glands of patients with Sjögren's syndrome. Consequently the CXCL13/LTBR axis is considered as a potential therapeutic target in conditions like Sjögren's syndrome. This is evidenced by the development of pharmaceutical agents that block LTBR activity being advanced to clinical trials (e.g. baminercept (BG9924; Biogen) which is a soluble LTBR-IgG Fc fusion protein [1]). BG9924, was primarily evaluated in clinical trials for active rheumatoid arthritis (RA; NCT00458861). However development in RA was terminated because interim analysis of trial data indicated that BG9924 therapy failed to meet the primary endpoint.